{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:34:01Z","timestamp":1792071241242,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.colsurfb.2020.110795","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T19:26:30Z","timestamp":1578943590000},"page":"110795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras"],"prefix":"10.1016","volume":"188","author":[{"given":"Yingming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-9416","authenticated-orcid":false,"given":"Wenyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2020.110795_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0010","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00018-015-2117-6","article-title":"Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs","volume":"73","author":"Bayliss","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"NATURE"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bmc.2015.12.004","article-title":"Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors","volume":"24","author":"Achary","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.onc.1200849","article-title":"Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system","volume":"14","author":"Iwahara","year":"1997","journal-title":"ONCOGENE"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0030","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0035","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in untreated ALK-Positive non-small-Cell lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0060","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0065","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s11523-017-0526-1","article-title":"The current landscape of anaplastic lymphoma kinase (ALK) in non-small cell lung Cancer: emerging treatment paradigms and future directions","volume":"12","author":"Qin","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0070","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Nat. Acad. Sci. U.S.A"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1021\/acs.jmedchem.8b01945","article-title":"Targeted degradation of MDM2 as a new approach to improve the efficacy of MDM2-p53 inhibitors","volume":"62","author":"Wurz","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0080","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate Cancer","volume":"62","author":"Han","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0090","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acschembio.8b01016","article-title":"Rapid and reversible knockdown of endogenously tagged endosomal proteins via an optimized HaloPROTAC degrader","volume":"14","author":"Tovell","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0095","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"SCIENCE"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0100","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC design for the degradation of oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angew. Chemie Int. Ed."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/cr.2016.31","article-title":"Drugging the undruggables: exploring the ubiquitin system for drug development","volume":"26","author":"Huang","year":"2016","journal-title":"Cell Res."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejmech.2019.04.036","article-title":"Small molecule PROTACs in targeted therapy: an emerging strategy to induce protein degradation","volume":"174","author":"Xi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0115","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","article-title":"Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK)","volume":"151","author":"Zhang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bbrc.2018.09.169","article-title":"Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)","volume":"505","author":"Kang","year":"2018","journal-title":"BIOCHEM BIOPH RES CO"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0125","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","article-title":"Chemically induced degradation of anaplastic lymphoma kinase (ALK)","volume":"61","author":"Powell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0135","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cbic.201000222","article-title":"Two-headed PROTAC: an effective new tool for targeted protein degradation","volume":"11","author":"Cyrus","year":"2010","journal-title":"CHEMBIOCHEM"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/mt.2014.30","article-title":"Gold nanoparticles for nucleic acid delivery","volume":"22","author":"Ding","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0145","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0150","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.1021\/ja075181k","article-title":"Paclitaxel-functionalized gold nanoparticles","volume":"129","author":"Gibson","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0155","doi-asserted-by":"crossref","first-page":"7879","DOI":"10.1039\/b914071a","article-title":"Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers","volume":"19","author":"Aryal","year":"2009","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0160","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.addr.2008.03.016","article-title":"Gold nanoparticles in delivery applications","volume":"60","author":"Ghosh","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/physci241020a0","article-title":"Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions","volume":"241","author":"Frens","year":"1973","journal-title":"Nat. Phys. Sci."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0170","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","article-title":"Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression","volume":"61","author":"Zhou","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0175","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/ac504081k","article-title":"Quantitative analysis of thiolated ligand exchange on gold nanoparticles monitored by 1H NMR spectroscopy","volume":"87","author":"Smith","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0180","doi-asserted-by":"crossref","first-page":"8569","DOI":"10.1021\/acsami.6b16669","article-title":"Performance of doxorubicin-conjugated gold nanoparticles: regulation of drug location","volume":"9","author":"Cui","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0185","doi-asserted-by":"crossref","first-page":"8629","DOI":"10.1021\/nn202155y","article-title":"Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment","volume":"5","author":"Ma","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.addr.2011.08.006","article-title":"Monolayer coated gold nanoparticles for delivery applications","volume":"64","author":"Rana","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0195","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1021\/ac0702084","article-title":"Determination of size and concentration of gold nanoparticles from UV-vis spectra","volume":"79","author":"Haiss","year":"2007","journal-title":"Anal. Chem."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0200","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1088\/0957-4484\/17\/16\/027","article-title":"Synthesis of metallic nanoparticles protected with N,N,N-trimethyl chitosan chloride via a relatively weak affinity","volume":"17","author":"Ding","year":"2006","journal-title":"NANOTECHNOLOGY"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0205","first-page":"261","article-title":"Process optimization of Pomalidomide","volume":"5","author":"Shi-kui","year":"2015","journal-title":"Strait Pharmaceutical Journal"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0210","series-title":"Solid State Forms Of Ceritinib And Salts Thereof","author":"Ivica","year":"2016"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0215","doi-asserted-by":"crossref","first-page":"10217","DOI":"10.1016\/j.biomaterials.2013.09.008","article-title":"The performance of thiol-terminated PEG-paclitaxel-conjugated gold nanoparticles","volume":"34","author":"Ding","year":"2013","journal-title":"BIOMATERIALS"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0220","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1016\/j.biomaterials.2009.07.048","article-title":"Gold nanoparticles with a monolayer of doxorubicin-conjugated amphiphilic block copolymer for tumor-targeted drug delivery","volume":"30","author":"Prabaharan","year":"2009","journal-title":"BIOMATERIALS"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0225","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.addr.2009.03.007","article-title":"Magnetic nanoparticles for theragnostics","volume":"61","author":"Shubayev","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0230","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1042\/BJ20090387","article-title":"Anaplastic lymphoma kinase: signalling in development and disease","volume":"420","author":"Palmer","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0235","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","article-title":"The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study","volume":"25","author":"Burslem","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0240","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0245","first-page":"7436","article-title":"DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics","volume":"6","author":"Latorre","year":"2014","journal-title":"Nano Scale"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0962-8924(98)01346-4","article-title":"Proteasome inhibitors: valuable new tools for cell biologists","volume":"8","author":"Lee","year":"1998","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0255","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","article-title":"Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma","volume":"6","author":"Christensen","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0260","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.colsurfb.2020.110795_bib0265","series-title":"The New Health Bioeconomy: R&D Policy and Innovation for the Twenty-first Century","author":"Mittra","year":"2015"},{"key":"10.1016\/j.colsurfb.2020.110795_bib0270","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776520300254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776520300254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:49:04Z","timestamp":1760525344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776520300254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":54,"alternative-id":["S0927776520300254"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2020.110795","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2020.110795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110795"}}